Skip to main content

Advertisement

SpringerLink
Log in

Sublingual Immunotherapy in Children

  • Otolaryngic Allergy (W Mims, Section Editor)
  • Published:
Current Otorhinolaryngology Reports Aims and scope Submit manuscript

Abstract

Allergic rhinitis and food allergies are two of the most prevalent chronic medical diseases affecting children. Poorly controlled allergic rhinitis symptoms may impact quality of life and missed school days. Recent clinical trials have demonstrated that sublingual immunotherapy is effective in decreasing hypersensitivity to allergens such as dust mite, pollens, and cockroach. Research evaluating efficacy of sublingual immunotherapy for peanuts is promising; however, sublingual immunotherapy for food allergy should only be performed in a research setting until further evidence demonstrates consistent safety. Sublingual immunotherapy is an effective and safe alternative to more traditional subcutaneous immunotherapy, is well tolerated, and has good compliance among pediatric patients. The majority of adverse events with sublingual immunotherapy are reported as minor and have a lower systemic complication rate compared to subcutaneous immunotherapy, an important consideration among children.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

SCIT:

Subcutaneous immunotherapy

SLIT:

Sublingual immunotherapy

FEV-1:

Forced end vital capacity at 1 s

ASI:

Allergen-specific immunotherapy

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Dl Blackwell, Lucas JW, Clarke TC. Summary health statistics for US adults: national health interview survey. Vital Health Stat. 2014;260:1–161.

    Google Scholar 

  2. Koh YY, Kim CK. The development of asthma in patients with allergic rhinitis. Curr Opin Allergy Clin Immunol. 2003;3:159–64.

    Article  PubMed  Google Scholar 

  3. Dykewicz M, Fineman S. Exectuvie summary of joint task force practice parameters on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol. 1998;81:463–8.

    Article  CAS  PubMed  Google Scholar 

  4. Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis. Otolaryngology. 2015;152(1S):S1–43.

    Google Scholar 

  5. Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Investig Allergol Clin Immunol. 2005;15:9–16.

    CAS  PubMed  Google Scholar 

  6. Frischemeyer-Guerrerio PA, Keet CA, Guerrerio AL, et al. Modulation of dendritic cell innate and adaptive immune functions by oral and sublingual immunotherapy. Clin Immunol. 2014;155:47–9.

    Article  Google Scholar 

  7. Akdis CA. Therapies for allergic inflammation: refining strategies to induce tolerance. Nat Med. 2012;18:736–49.

    Article  CAS  PubMed  Google Scholar 

  8. Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis to house dust mite. Clin Allergy. 1986;16:483–91.

    Article  CAS  PubMed  Google Scholar 

  9. Fiocchi A, Fox AT. Preventing progression of allergic rhinitis: the role of specific immunotherapy. Arch Dis Child Educ Pract Ed. 2011;96:91–100.

    Article  PubMed  Google Scholar 

  10. Blaiss M, Maloney J, Nolte H. Efficacy and safety of timothy grass allergy immunotherapy tablets in north American children and adolescents. J Allergy Clin Immunol. 2011;127:64–71.

    Article  CAS  PubMed  Google Scholar 

  11. Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009;123:160–6.

    Article  CAS  PubMed  Google Scholar 

  12. Linkov G, Toskala E. Sublingual immunotherapy: what we can learn from the European experience. Curr Opin Otolaryngol Head Neck Surg. 2014;22:208–10.

    Article  PubMed  Google Scholar 

  13. •• Kim JM, Lin SY, Suarez-Cuervo C, et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Pediatrics. 2013;131:1155–67. High strength of evidence that SLIT improves asthma symptoms. Moderate strength of evidence that SLIT improves rhinitis and conjunctivitis symptoms and low strength of evidence to support SCIT over SLIT as primary therapy.

  14. De Castro G, Zicari AM, Indinnimeo L, et al. Efficacy of sublingual specific immunotherapy on allergic asthma and rhinitis in children’s real life. Eur Rev Med Pharmacol Sci. 2013;17:2225–31.

    PubMed  Google Scholar 

  15. Aydogan M, Eifan AO, Keles S, et al. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomized trial. Respir Med. 2013;107:1322–9.

    Article  PubMed  Google Scholar 

  16. • Yukselen A, Kendirli SG, Yilmaz M et al. Two year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing subcutaneous and sublingual immunotherapy. Asian Pac J Allergy Immunol. 2013;31:233–41. Children who received 24 months of SLIT showed a 28% median reduction in rhinitis and asthma symptoms compared to only 12 months of SCIT, implying that a longer duration of therapy with SLIT was necessary to achieve similar effect.

  17. Corzo JL, Carrillo T, Pedemonte C, et al. Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children. J Investig Allergol Clin Immunol. 2014;24(3):154–61.

    CAS  PubMed  Google Scholar 

  18. • Rienzo VD, Cadario G, Grieco T et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, open, parallel-group study. Ann Allergy Asthma Immunol. 2014;113:671–2. After 72 weeks of SLIT, children were observed to have a reduction in atopic dermatitis scores.

  19. Holt PG, Sly PD, Sampson HA, et al. Prophylactic use of sublingual allergen immunotherapy in high-risk children: a pilot study. J Allergy Clin Immunol. 2013;132(4):991–4.

    Article  CAS  PubMed  Google Scholar 

  20. Tosca M, Silvestri M, Accogli A, Rossi GA, Ciprandi G. Serum-specific IgE and allergen and immunotherapy in allergic children. Immunotherapy. 2014;6(1):29–33.

    Article  CAS  PubMed  Google Scholar 

  21. Rosenstreich DL, Eggleston P, Kattan M, et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med. 1997;336:1356–63.

    Article  CAS  PubMed  Google Scholar 

  22. •• Wood RA, Togias A, Wildfire J, et al. Development of cockroach immunotherapy by the inner-city asthma consortium. J Allergy Clin Immunol. 2013;133(1): 846–52. 40 % of Children undergoing rapid escalation of cockroach SLIT showed nearly three-fold increase in allergen specific IgE levels.

  23. •• Maloney J, Bernstein DI, Nelson H, et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol. 2014;112:146-153. Among children receiving SLIT, there was a 32 % reduction in total rhinoconjunctivitis score.

  24. Frati F, Ridolo E, Fuiano N, et al. Safety of sublingual immunotherapy in children. Expert Opin Drug Saf. 2014;13(7):947–53.

    Article  CAS  PubMed  Google Scholar 

  25. Calderon MA, Simons FER, Malling HJ, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012;67:303–11.

    Google Scholar 

  26. •• Fleischer DM, Burks AW, Vickery BP et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol. 2013;131(1):119–27. After 44 weeks of SLIT, 70 % of participants responded, with median successfully consumed peanut dose increasing from 3.5 mg to 496 mg. After 68 weeks of therapy, median successfully consumed peanut dose increased to 996 mg.

  27. Chin SJ, Bickery BP, Kulis MD, et al. Sublingual versus oral immunotherapy for peanut-allergic children: a retrospective comparison. J Allergy Clin Immunol. 2013;132(2):476–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Sampson HA, Acevves S, Bock SA, et al. Food allergy: a practice parameter update-2014. J Allergy Clin Immunol. 2014;134(5):1016–25.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Otolaryngology-Head & Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, 601 N. Caroline Street, 6th Floor, Baltimore, MD, 21287, USA

    David J. Mener & Sandra Y. Lin

Authors
  1. David J. Mener
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sandra Y. Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sandra Y. Lin.

Additional information

This article is part of the Topical Collection on Otolaryngic Allergy.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mener, D.J., Lin, S.Y. Sublingual Immunotherapy in Children. Curr Otorhinolaryngol Rep 3, 155–161 (2015). https://doi.org/10.1007/s40136-015-0087-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40136-015-0087-8

Keywords

Search

Navigation